> top > docs > PubMed:32676976 > annotations

PubMed:32676976 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 390-393 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T2 795-799 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T3 947-950 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T4 967-970 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T5 1141-1144 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T6 1195-1198 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T7 1212-1215 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 390-393 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T2 795-799 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T3 947-950 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T4 967-970 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T5 1141-1144 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T6 1195-1198 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T7 1212-1215 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 46-54 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T2 203-238 Disease denotes acute respiratory distress syndrome http://purl.obolibrary.org/obo/MONDO_0006502
T3 209-238 Disease denotes respiratory distress syndrome http://purl.obolibrary.org/obo/MONDO_0009971
T4 240-244 Disease denotes ARDS http://purl.obolibrary.org/obo/MONDO_0006502
T5 249-257 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T6 288-292 Disease denotes ARDS http://purl.obolibrary.org/obo/MONDO_0006502
T7 773-777 Disease denotes ARDS http://purl.obolibrary.org/obo/MONDO_0006502
T8 800-806 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T9 826-834 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T10 1341-1345 Disease denotes ARDS http://purl.obolibrary.org/obo/MONDO_0006502
T11 1485-1489 Disease denotes ARDS http://purl.obolibrary.org/obo/MONDO_0006502
T12 1493-1501 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 56-57 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T2 87-97 http://purl.obolibrary.org/obo/BFO_0000030 denotes OBJECTIVES
T3 110-111 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T4 277-278 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T5 361-362 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T6 390-393 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T7 409-413 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arms
T8 438-439 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T9 576-577 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T10 578-585 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T11 668-672 http://purl.obolibrary.org/obo/CLO_0001757 denotes at 1
T12 795-799 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T13 795-799 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T14 947-950 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T15 959-966 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T16 967-970 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T17 1099-1100 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T18 1110-1112 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T19 1141-1144 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T20 1195-1198 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T21 1204-1211 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T22 1212-1215 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T23 1226-1227 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T24 1295-1296 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 124-132 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T2 144-148 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T3 305-309 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T4 457-462 Chemical denotes alpha http://purl.obolibrary.org/obo/CHEBI_30216
T5 463-473 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T6 509-528 Chemical denotes lopinavir/ritonavir http://purl.obolibrary.org/obo/CHEBI_145924
T7 509-518 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T8 519-528 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T9 700-705 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-55 Sentence denotes Exploring an Integrative Therapy for Treating COVID-19:
T2 56-86 Sentence denotes A Randomized Controlled Trial.
T3 87-98 Sentence denotes OBJECTIVES:
T4 99-267 Sentence denotes To develop a new Chinese medicine (CM)-based drug and to evaluate its safety and effect for suppressing acute respiratory distress syndrome (ARDS) in COVID-19 patients.
T5 268-276 Sentence denotes METHODS:
T6 277-400 Sentence denotes A putative ARDS-suppressing drug Keguan-1 was first developed and then evaluated by a randomized, controlled two-arm trial.
T7 401-706 Sentence denotes The two arms of the trial consist of a control therapy (alpha interferon inhalation, 50 µg twice daily; and lopinavir/ritonavir, 400 and 100 mg twice daily, respectively) and a testing therapy (control therapy plus Keguan-1 19.4 g twice daily) by random number table at 1:1 ratio with 24 cases each group.
T8 707-858 Sentence denotes After 2-week treatment, adverse events, time to fever resolution, ARDS development, and lung injury on newly diagnosed COVID-19 patients were assessed.
T9 859-867 Sentence denotes RESULTS:
T10 868-1042 Sentence denotes An analysis of the data from the first 30 participants showed that the control arm and the testing arm did not exhibit any significant differences in terms of adverse events.
T11 1043-1146 Sentence denotes Based on this result, the study was expanded to include a total of 48 participants (24 cases each arm).
T12 1147-1356 Sentence denotes The results show that compared with the control arm, the testing arm exhibited a significant improvement in time to fever resolution (P=0.035), and a significant reduction in the development of ARDS (P=0.048).
T13 1357-1369 Sentence denotes CONCLUSIONS:
T14 1370-1535 Sentence denotes Keguan-1-based integrative therapy was safe and superior to the standard therapy in suppressing the development of ARDS in COVID-19 patients. (Trial registration No.
T15 1536-1576 Sentence denotes NCT04251871 at www.clinicaltrials.gov ).

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 209-229 Phenotype denotes respiratory distress http://purl.obolibrary.org/obo/HP_0002098
T2 755-760 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T3 1263-1268 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945